(-)-epigallocatechin 3-gallate multiple interactions ISO RGD:1353532 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KAT6B mRNA CTD PMID:22079256 (S)-nicotine multiple interactions ISO RGD:1617572 6480464 [Nicotine co-treated with 1-Methyl-4-phenyl-1 more ... CTD PMID:20230807 1,2-dichloroethane increases expression ISO RGD:1617572 6480464 ethylene dichloride results in increased expression of KAT6B mRNA CTD PMID:28960355 1,2-dimethylhydrazine decreases expression ISO RGD:1617572 6480464 1, 2-Dimethylhydrazine results in decreased expression of KAT6B mRNA CTD PMID:22206623 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine decreases expression ISO RGD:1617572 6480464 1-Methyl-4-phenyl-1 more ... CTD PMID:20230807 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine multiple interactions ISO RGD:1617572 6480464 [Nicotine co-treated with 1-Methyl-4-phenyl-1 more ... CTD PMID:20230807 2,2',4,4'-Tetrabromodiphenyl ether decreases expression ISO RGD:1353532 6480464 2 more ... CTD PMID:23146750 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1617572 6480464 Tetrachlorodibenzodioxin affects the expression of KAT6B mRNA CTD PMID:21570461 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1617572 6480464 [Tetrachlorodibenzodioxin affects the methylation of KAT6B intron] which results in decreased expression of KAT6B mRNA CTD PMID:33017471 4,4'-sulfonyldiphenol multiple interactions EXP 6480464 [bisphenol A co-treated with bisphenol F co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of KAT6B mRNA CTD PMID:36041667 adefovir pivoxil decreases expression ISO RGD:1353532 6480464 adefovir dipivoxil results in decreased expression of KAT6B mRNA CTD PMID:25596134 aflatoxin B1 increases expression ISO RGD:1617572 6480464 Aflatoxin B1 results in increased expression of KAT6B mRNA CTD PMID:19770486 aflatoxin B1 increases methylation ISO RGD:1353532 6480464 Aflatoxin B1 results in increased methylation of KAT6B intron CTD PMID:30157460 aflatoxin B1 decreases methylation ISO RGD:1353532 6480464 Aflatoxin B1 results in decreased methylation of KAT6B gene CTD PMID:27153756 aldehydo-D-glucose multiple interactions ISO RGD:1617572 6480464 [Glucose co-treated with INS1 protein] affects the expression of KAT6B mRNA CTD PMID:22951486 all-trans-retinoic acid increases expression ISO RGD:1353532 6480464 Tretinoin results in increased expression of KAT6B mRNA CTD PMID:23724009 antirheumatic drug increases expression ISO RGD:1353532 6480464 Antirheumatic Agents results in increased expression of KAT6B mRNA CTD PMID:24449571 aristolochic acid A decreases expression ISO RGD:1353532 6480464 aristolochic acid I results in decreased expression of KAT6B mRNA CTD PMID:33212167 arsenite(3-) multiple interactions ISO RGD:1353532 6480464 arsenite inhibits the reaction [G3BP1 protein binds to KAT6B mRNA] CTD PMID:32406909 arsenous acid decreases expression ISO RGD:1353532 6480464 Arsenic Trioxide results in decreased expression of KAT6B mRNA CTD PMID:15761015 arsenous acid increases expression ISO RGD:1353532 6480464 Arsenic Trioxide results in increased expression of KAT6B mRNA CTD PMID:20458559 atrazine affects methylation EXP 6480464 Atrazine affects the methylation of KAT6B gene CTD PMID:28931070 benzo[a]pyrene increases mutagenesis ISO RGD:1353532 6480464 Benzo(a)pyrene results in increased mutagenesis of KAT6B gene CTD PMID:25435355 benzo[a]pyrene affects methylation ISO RGD:1353532 6480464 Benzo(a)pyrene affects the methylation of KAT6B intron CTD PMID:30157460 benzo[a]pyrene increases methylation ISO RGD:1617572 6480464 Benzo(a)pyrene results in increased methylation of KAT6B intron CTD PMID:27901495 benzo[a]pyrene increases expression ISO RGD:1617572 6480464 Benzo(a)pyrene results in increased expression of KAT6B mRNA CTD PMID:22228805 benzo[a]pyrene diol epoxide I affects expression ISO RGD:1353532 6480464 7 more ... CTD PMID:20382639 bisphenol A affects expression EXP 6480464 bisphenol A affects the expression of KAT6B mRNA CTD PMID:25181051 , PMID:30816183 bisphenol A multiple interactions EXP 6480464 [bisphenol A co-treated with bisphenol F co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of KAT6B mRNA CTD PMID:36041667 bisphenol A multiple interactions ISO RGD:1353532 6480464 [bisphenol A co-treated with Fulvestrant] results in decreased methylation of KAT6B gene CTD PMID:31601247 bisphenol A decreases methylation ISO RGD:1353532 6480464 bisphenol A results in decreased methylation of KAT6B gene CTD PMID:31601247 bisphenol A decreases expression ISO RGD:1617572 6480464 bisphenol A results in decreased expression of KAT6B mRNA CTD PMID:33221593 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of KAT6B mRNA CTD PMID:34947998 bisphenol A increases expression ISO RGD:1353532 6480464 bisphenol A results in increased expression of KAT6B mRNA CTD PMID:29275510 bisphenol F multiple interactions EXP 6480464 [bisphenol A co-treated with bisphenol F co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of KAT6B mRNA CTD PMID:36041667 bleomycin A5 decreases expression ISO RGD:1353532 6480464 bleomycetin results in decreased expression of KAT6B mRNA CTD PMID:21040473 bortezomib decreases expression ISO RGD:1353532 6480464 Bortezomib results in decreased expression of KAT6B mRNA CTD PMID:20977926 butanal decreases expression ISO RGD:1353532 6480464 butyraldehyde results in decreased expression of KAT6B mRNA CTD PMID:26079696 cadmium dichloride decreases expression ISO RGD:1353532 6480464 Cadmium Chloride results in decreased expression of KAT6B mRNA CTD PMID:25596134 caffeine affects phosphorylation ISO RGD:1353532 6480464 Caffeine affects the phosphorylation of KAT6B protein CTD PMID:35688186 carbamazepine affects expression ISO RGD:1353532 6480464 Carbamazepine affects the expression of KAT6B mRNA CTD PMID:24752500 carbon nanotube decreases expression ISO RGD:1617572 6480464 Nanotubes, Carbon analog results in decreased expression of KAT6B mRNA CTD PMID:25554681 chloroacetaldehyde decreases expression ISO RGD:1353532 6480464 chloroacetaldehyde results in decreased expression of KAT6B mRNA CTD PMID:25596134 choline multiple interactions ISO RGD:1617572 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of KAT6B gene CTD PMID:20938992 cidofovir anhydrous decreases expression ISO RGD:1353532 6480464 Cidofovir results in decreased expression of KAT6B mRNA CTD PMID:25596134 cisplatin decreases expression ISO RGD:1353532 6480464 Cisplatin results in decreased expression of KAT6B mRNA CTD PMID:25596134 clothianidin decreases expression ISO RGD:1353532 6480464 clothianidin results in decreased expression of KAT6B mRNA CTD PMID:31626844 D-glucose multiple interactions ISO RGD:1617572 6480464 [Glucose co-treated with INS1 protein] affects the expression of KAT6B mRNA CTD PMID:22951486 diarsenic trioxide decreases expression ISO RGD:1353532 6480464 Arsenic Trioxide results in decreased expression of KAT6B mRNA CTD PMID:15761015 diarsenic trioxide increases expression ISO RGD:1353532 6480464 Arsenic Trioxide results in increased expression of KAT6B mRNA CTD PMID:20458559 diclofenac affects expression ISO RGD:1353532 6480464 Diclofenac affects the expression of KAT6B mRNA CTD PMID:24752500 dicrotophos increases expression ISO RGD:1353532 6480464 dicrotophos results in increased expression of KAT6B mRNA CTD PMID:28302478 dioxygen increases expression ISO RGD:1353532 6480464 Oxygen deficiency results in increased expression of KAT6B mRNA CTD PMID:25596134 dorsomorphin multiple interactions ISO RGD:1353532 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 doxorubicin decreases expression ISO RGD:1353532 6480464 Doxorubicin results in decreased expression of KAT6B mRNA CTD PMID:29803840 entinostat decreases expression ISO RGD:1353532 6480464 entinostat results in decreased expression of KAT6B mRNA CTD PMID:27188386 folic acid multiple interactions ISO RGD:1617572 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of KAT6B gene CTD PMID:20938992 formaldehyde decreases expression ISO RGD:1353532 6480464 Formaldehyde results in decreased expression of KAT6B mRNA CTD PMID:20655997 fulvestrant multiple interactions ISO RGD:1353532 6480464 [bisphenol A co-treated with Fulvestrant] results in decreased methylation of KAT6B gene CTD PMID:31601247 gallic acid decreases expression ISO RGD:1353532 6480464 Gallic Acid results in decreased expression of KAT6B mRNA CTD PMID:34408198 glucose multiple interactions ISO RGD:1617572 6480464 [Glucose co-treated with INS1 protein] affects the expression of KAT6B mRNA CTD PMID:22951486 ifosfamide decreases expression ISO RGD:1353532 6480464 Ifosfamide results in decreased expression of KAT6B mRNA CTD PMID:25596134 L-methionine multiple interactions ISO RGD:1617572 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of KAT6B gene CTD PMID:20938992 N,N-diethyl-m-toluamide multiple interactions EXP 6480464 [Permethrin co-treated with DEET] results in decreased methylation of KAT6B gene CTD PMID:33148267 nickel atom decreases expression ISO RGD:1353532 6480464 Nickel results in decreased expression of KAT6B mRNA CTD PMID:25583101 nicotine multiple interactions ISO RGD:1617572 6480464 [Nicotine co-treated with 1-Methyl-4-phenyl-1 more ... CTD PMID:20230807 ozone multiple interactions ISO RGD:1617572 6480464 [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in decreased expression of KAT6B mRNA CTD PMID:34911549 paracetamol increases expression ISO RGD:1353532 6480464 Acetaminophen results in increased expression of KAT6B mRNA CTD PMID:26690555 perfluorohexanesulfonic acid decreases expression ISO RGD:1353532 6480464 perfluorohexanesulfonic acid results in decreased expression of KAT6B mRNA CTD PMID:25812627 perfluorononanoic acid decreases expression ISO RGD:1353532 6480464 perfluoro-n-nonanoic acid results in decreased expression of KAT6B mRNA CTD PMID:25812627 perfluorooctane-1-sulfonic acid decreases expression ISO RGD:1353532 6480464 perfluorooctane sulfonic acid results in decreased expression of KAT6B mRNA CTD PMID:25812627 perfluorooctanoic acid decreases expression ISO RGD:1353532 6480464 perfluorooctanoic acid results in decreased expression of KAT6B mRNA CTD PMID:25812627 permethrin multiple interactions EXP 6480464 [Permethrin co-treated with DEET] results in decreased methylation of KAT6B gene CTD PMID:33148267 phenobarbital affects expression ISO RGD:1617572 6480464 Phenobarbital affects the expression of KAT6B mRNA CTD PMID:23091169 PhIP increases expression ISO RGD:1353532 6480464 2-amino-1-methyl-6-phenylimidazo(4, 5-b)pyridine results in increased expression of KAT6B mRNA CTD PMID:20816883 picoxystrobin decreases expression ISO RGD:1353532 6480464 picoxystrobin results in decreased expression of KAT6B mRNA CTD PMID:33512557 pirinixic acid increases expression ISO RGD:1617572 6480464 pirinixic acid results in increased expression of KAT6B mRNA CTD PMID:20813756 potassium chromate multiple interactions ISO RGD:1353532 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KAT6B mRNA CTD PMID:22079256 potassium chromate decreases expression ISO RGD:1353532 6480464 potassium chromate(VI) results in decreased expression of KAT6B mRNA CTD PMID:22079256 pyrimidifen decreases expression ISO RGD:1353532 6480464 pyrimidifen results in decreased expression of KAT6B mRNA CTD PMID:33512557 sarin decreases expression ISO RGD:1353532 6480464 Sarin results in decreased expression of KAT6B mRNA CTD PMID:19522546 sarin increases expression ISO RGD:1353532 6480464 Sarin results in increased expression of KAT6B mRNA CTD PMID:19522546 SB 431542 multiple interactions ISO RGD:1353532 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 sodium arsenite decreases expression ISO RGD:1353532 6480464 sodium arsenite results in decreased expression of KAT6B mRNA CTD PMID:28595984 , PMID:34032870 sodium arsenite affects expression ISO RGD:1353532 6480464 sodium arsenite affects the expression of KAT6B mRNA CTD PMID:29319823 tetrachloromethane decreases expression EXP 6480464 Carbon Tetrachloride results in decreased expression of KAT6B mRNA CTD PMID:33387578 trichostatin A decreases expression ISO RGD:1353532 6480464 trichostatin A results in decreased expression of KAT6B mRNA CTD PMID:24935251 more ... trichostatin A multiple interactions ISO RGD:1353532 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6B mRNA CTD PMID:27188386 triptonide increases expression ISO RGD:1617572 6480464 triptonide results in increased expression of KAT6B mRNA CTD PMID:33045310 valproic acid affects expression ISO RGD:1353532 6480464 Valproic Acid affects the expression of KAT6B mRNA CTD PMID:25979313 valproic acid decreases expression ISO RGD:1353532 6480464 Valproic Acid results in decreased expression of KAT6B mRNA CTD PMID:23179753 more ... valproic acid multiple interactions ISO RGD:1353532 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6B mRNA CTD PMID:27188386 vinclozolin affects expression EXP 6480464 vinclozolin affects the expression of KAT6B mRNA CTD PMID:19015723 vorinostat decreases expression ISO RGD:1353532 6480464 vorinostat results in decreased expression of KAT6B mRNA CTD PMID:27188386